Literature DB >> 20875492

Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania.

Timothy Lahey1, Robert D Arbeit, Muhammad Bakari, C Robert Horsburgh, Mecky Matee, Richard Waddell, Lillian Mtei, Jenni M Vuola, Kisali Pallangyo, C Fordham von Reyn.   

Abstract

Preventive immunization with whole inactivated Mycobacterium vaccae (MV) confers protection against HIV-associated tuberculosis (TB) in BCG-immunized adults with CD4 counts ≥200 cells/μl. We evaluated the immunogenicity of MV in the 2013 subjects of the phase III DarDarTrial using an interferon gamma (IFN-γ) enzyme linked immunosorbent assay (ELISA), tritiated thymidine lymphocyte proliferation assay (LPA) and an ELISA for antibodies to the TB glycolipid lipoarabinomannan (LAM). MV immunization boosts IFN-γ and LPA responses to MV sonicate, and antibody responses to LAM. Post-immunization immune responses to MV correlated with baseline clinical factors, but the responses did not predict protection from HIV-associated TB.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20875492      PMCID： PMC2981786          DOI： 10.1016/j.vaccine.2010.09.041

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  47 in total

1.  The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma.

Authors:  L Camporota; A Corkhill; H Long; J Lordan; L Stanciu; N Tuckwell; A Cross; J L Stanford; G A W Rook; S T Holgate; R Djukanovic
Journal:  Eur Respir J       Date:  2003-02       Impact factor: 16.671

2.  BCG vaccination in tuberculous households.

Authors:  S R ROSENTHAL; E LOEWINSOHN; M L GRAHAM; D LIVERIGHT; M G THORNE; V JOHNSON
Journal:  Am Rev Respir Dis       Date:  1961-11

3.  A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers.

Authors:  Daniel F Hoft; Azra Blazevic; Getahun Abate; Willem A Hanekom; Gilla Kaplan; Jorge H Soler; Frank Weichold; Larry Geiter; Jerald C Sadoff; Marcus A Horwitz
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

4.  A comparison of IFNgamma detection methods used in tuberculosis vaccine trials.

Authors:  Natalie E R Beveridge; Helen A Fletcher; Jane Hughes; Ansar A Pathan; Thomas J Scriba; Angela Minassian; Clare R Sander; Kathryn T Whelan; Hazel M Dockrell; Adrian V S Hill; Willem A Hanekom; Helen McShane
Journal:  Tuberculosis (Edinb)       Date:  2008-09-17       Impact factor: 3.131

5.  Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns.

Authors:  Benjamin M N Kagina; Brian Abel; Thomas J Scriba; Elizabeth J Hughes; Alana Keyser; Andreia Soares; Hoyam Gamieldien; Mzwandile Sidibana; Mark Hatherill; Sebastian Gelderbloem; Hassan Mahomed; Anthony Hawkridge; Gregory Hussey; Gilla Kaplan; Willem A Hanekom
Journal:  Am J Respir Crit Care Med       Date:  2010-06-17       Impact factor: 21.405

Review 6.  Advances in tuberculosis vaccine strategies.

Authors:  Yasir A W Skeiky; Jerald C Sadoff
Journal:  Nat Rev Microbiol       Date:  2006-06       Impact factor: 60.633

7.  HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine.

Authors:  Nazma Mansoor; Thomas J Scriba; Marwou de Kock; Michele Tameris; Brian Abel; Alana Keyser; Francesca Little; Andreia Soares; Sebastian Gelderbloem; Silvia Mlenjeni; Lea Denation; Anthony Hawkridge; W Henry Boom; Gilla Kaplan; Gregory D Hussey; Willem A Hanekom
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

8.  Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial.

Authors:  Jenni M Vuola; Matti A Ristola; Bernard Cole; Annika Järviluoma; Susan Tvaroha; Terhi Rönkkö; Outi Rautio; Robert D Arbeit; C Fordham von Reyn
Journal:  AIDS       Date:  2003-11-07       Impact factor: 4.177

9.  Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection.

Authors:  Christof Geldmacher; Alexandra Schuetz; Njabulo Ngwenyama; Joseph P Casazza; Erica Sanga; Elmar Saathoff; Catharina Boehme; Steffen Geis; Leonard Maboko; Mahavir Singh; Fred Minja; Andreas Meyerhans; Richard A Koup; Michael Hoelscher
Journal:  J Infect Dis       Date:  2008-12-01       Impact factor: 5.226

10.  Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis.

Authors:  Timothy Lahey; Mecky Matee; Lillian Mtei; Muhammad Bakari; Kisali Pallangyo; C Fordham von Reyn
Journal:  BMC Infect Dis       Date:  2009-02-23       Impact factor: 3.090
View more
  19 in total

1.  A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults.

Authors:  Thomas J Scriba; Michele Tameris; Erica Smit; Linda van der Merwe; E Jane Hughes; Blessing Kadira; Katya Mauff; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Humphrey Mulenga; Marwou de Kock; Lebohang Makhethe; Esme Janse van Rensburg; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Hendrik Geldenhuys; Adrian V S Hill; Anthony Hawkridge; Gregory D Hussey; Willem A Hanekom; Helen McShane; Hassan Mahomed
Journal:  Am J Respir Crit Care Med       Date:  2012-01-26       Impact factor: 21.405

2.  Auditory impairments in HIV-infected individuals in Tanzania.

Authors:  Isaac I Maro; Ndeserua Moshi; Odile H Clavier; Todd A MacKenzie; Robert J Kline-Schoder; Jed C Wilbur; Robert D Chambers; Abigail M Fellows; Benjamin G Jastrzembski; John E Mascari; Muhammad Bakari; Mecky Matee; Frank E Musiek; Richard D Waddell; C Fordham von Reyn; Jay C Buckey
Journal:  Ear Hear       Date:  2014 May-Jun       Impact factor: 3.570

3.  Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis.

Authors:  Timothy Lahey; Todd Mackenzie; Robert D Arbeit; Muhammad Bakari; Lillian Mtei; Mecky Matee; Isaac Maro; C Robert Horsburgh; Kisali Pallangyo; C Fordham von Reyn
Journal:  Clin Infect Dis       Date:  2012-09-12       Impact factor: 9.079

4.  Greater preexisting interferon γ responses to mycobacterial antigens and lower bacillary load during HIV-associated tuberculosis.

Authors:  Timothy Lahey; Tom Czechura; Scott Crabtree; Robert D Arbeit; Mecky Matee; C Robert Horsburgh; Todd MacKenzie; Muhammad Bakari; Kisali Pallangyo; C Fordham von Reyn
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

Review 5.  Tuberculosis vaccines and prevention of infection.

Authors:  Thomas R Hawn; Tracey A Day; Thomas J Scriba; Mark Hatherill; Willem A Hanekom; Thomas G Evans; Gavin J Churchyard; James G Kublin; Linda-Gail Bekker; Steven G Self
Journal:  Microbiol Mol Biol Rev       Date:  2014-12       Impact factor: 11.056

6.  An Update on Tuberculosis Vaccines.

Authors:  Radha Gopalaswamy; Selvakumar Subbian
Journal:  Methods Mol Biol       Date:  2022

7.  Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma.

Authors:  Ferdinando C M Cananzi; Satvinder Mudan; Mary Dunne; Nneka Belonwu; Angus G Dalgleish
Journal:  Hum Vaccin Immunother       Date:  2013-07-09       Impact factor: 3.452

Review 8.  Current status of new tuberculosis vaccine in children.

Authors:  Yu Pang; Aihua Zhao; Chad Cohen; Wanli Kang; Jie Lu; Guozhi Wang; Yanlin Zhao; Suhua Zheng
Journal:  Hum Vaccin Immunother       Date:  2016-03-22       Impact factor: 3.452

Review 9.  Moving tuberculosis vaccines from theory to practice.

Authors:  Peter Andersen; Thomas J Scriba
Journal:  Nat Rev Immunol       Date:  2019-09       Impact factor: 53.106

10.  Protection against tuberculosis in Eurasian wild boar vaccinated with heat-inactivated Mycobacterium bovis.

Authors:  Joseba M Garrido; Iker A Sevilla; Beatriz Beltrán-Beck; Esmeralda Minguijón; Cristina Ballesteros; Ruth C Galindo; Mariana Boadella; Konstantin P Lyashchenko; Beatriz Romero; Maria Victoria Geijo; Francisco Ruiz-Fons; Alicia Aranaz; Ramón A Juste; Joaquín Vicente; José de la Fuente; Christian Gortázar
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.